Piper Jaffray Analyst: Why I Downgraded Valeant to Sell

The transcript discusses a company's shifting commentary on its business segments, highlighting weaknesses in traditionally strong areas like Gastroenterology and Western Europe. It notes changes in growth strategies, with dermatology no longer a key focus. The potential impact of a partnership with Walgreens is explored, emphasizing uncertainty in future growth and the role of pricing strategies.

What was the significance of the Dermatology business in the company's growth strategy?

What challenges does the company face in predicting its growth moving forward?